1 of 23

ATHENA–MONO (GOG-3020/ENGOT-ov45): <br />A Randomized, Double-blind, Phase 3 Trial Evaluating Rucaparib Monotherapy Vs Placebo As Maintenance Treatment Following Response To First-line <br />Platinum-based Chemotherapy In Ovarian Cancer

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

2 of 23

Background

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

3 of 23

ATHENA–MONO Study Schema

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

4 of 23

ATHENA–MONO Study Schema

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

5 of 23

Step-down Analysis for Efficacy Endpoints

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

6 of 23

Baseline Demographics and Disease Characteristics

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

7 of 23

Baseline Demographics and Disease Characteristics (Continued)

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

8 of 23

Patient Disposition

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

9 of 23

Primary Endpoint – Investigator-Assessed PFS: HRD Population

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

10 of 23

Primary Endpoint – Investigator-Assessed PFS: ITT Population

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

11 of 23

Secondary Endpoint – BICR-Assessed PFS

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

12 of 23

Investigator-Assessed PFS:<br />Exploratory Subgroups

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

13 of 23

BICR-Assessed PFS:<br />Exploratory Subgroups

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

14 of 23

Investigator-Assessed PFS: Exploratory Subgroups

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

15 of 23

Investigator-Assessed Objective Response

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

16 of 23

Summary of Safety

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

17 of 23

Most Common TEAEs (≥15% Any Grade)

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

18 of 23

Laboratory Parameters: ALT/AST

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

19 of 23

Rucaparib Dose Intensity in ATHENA–MONO

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

20 of 23

Change From Baseline in FACT-O TOI Score:<br />ITT Population

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

21 of 23

Conclusions

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

22 of 23

Acknowledgements

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

23 of 23

Slide 23

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.